Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma

Elevated local and circulating levels of transforming growth factor (TGF)‐β1 have been associated with cancer invasion, progression, and metastasis. The authors tested the hypothesis that preoperative plasma TGF‐β1 levels would independently predict cancer stage and prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.

[1]  T. Wheeler,et al.  Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder , 2001, Cancer.

[2]  M. Kattan,et al.  Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[5]  R. Clough,et al.  Plasma transforming growth factor‐β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma , 1999, Cancer.

[6]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[7]  W. Catalona,et al.  Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. , 1998, The Journal of urology.

[8]  M. Kattan,et al.  Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. , 1998, Human pathology.

[9]  R. Hautmann,et al.  Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? , 1998, The Journal of urology.

[10]  K. Junker,et al.  Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. , 1998, Cytokine.

[11]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[12]  O. Yoshida,et al.  Elevation of serum transforming growth factor-β1 Level in patients with metastatic prostate cancer. , 1996, Urologic oncology.

[13]  H. Klocker,et al.  Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. , 1996, The Journal of urology.

[14]  A. Melman,et al.  Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. , 1995, Nature medicine.

[15]  Y. Matsuzawa,et al.  Plasma transforming growth factor‐β1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases , 1994, Cancer.

[16]  R. Ackermann,et al.  [Value of computerized tomography in detection of lymph node metastases in bladder cancer]. , 1994, Der Urologe (Ausg. A).

[17]  R. Dodge,et al.  Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. , 1994, The Journal of urology.

[18]  R. Dodge,et al.  The value of pathologic factors in predicting cancer‐specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate , 1993, Cancer.

[19]  E. Crawford,et al.  Current management of invasive and metastatic transitional cell carcinoma of the bladder. , 1993, The Journal of urology.

[20]  D. Gillatt,et al.  Magnetic resonance imaging in the staging of bladder cancer. , 1993, British journal of urology.

[21]  S. Groshen,et al.  The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. , 1993, The Journal of urology.

[22]  P. Bassi,et al.  Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. , 1991, The Journal of urology.

[23]  J. Richie,et al.  Biology and management of bladder cancer. , 1990, The New England journal of medicine.

[24]  P. Alken,et al.  Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. , 1989, The Journal of urology.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  M. Nurmi,et al.  Antireflux ureteroileal anastomosis in ileal conduit urinary diversion and in ileocystoplasty following cystoprostatectomy. , 1988, Scandinavian Journal of Urology and Nephrology.

[27]  M. Nurmi,et al.  Reliability of CT in preoperative evaluation of bladder carcinoma. , 1988, Scandinavian journal of urology and nephrology.

[28]  C. Hodges,et al.  Radical cystectomy for bladder cancer. , 1978, The Journal of urology.